title: Hyperthermia generated with ferucarbotran (Resovist®) in an alternating magnetic field enhances cisplatin-induced apoptosis of cultured human oral cancer cells.
abstract: Hyperthermia is a promising anti-cancer treatment in which the tissue temperature is increased to 42-45 °C, and which is often used in combination with chemotherapy or radiation therapy. Our aim in the present work was to examine the feasibility of combination therapy for oral cancer with cisplatin and hyperthermia generated with ferucarbotran (Resovist(®); superparamagnetic iron oxide) in an alternating magnetic field (AMF). First, we established that administration of ferucarbotran at the approved dosage for magnetic resonance imaging provides an iron concentration sufficient to increase the temperature to 42.5 °C upon exposure to AMF. Then, we examined the effect of cisplatin combined with ferucarbotran/AMF-induced hyperthermia on cultured human oral cancer cells (HSC-3 and OSC-19). Cisplatin alone induced apoptosis of cancer cells in a dose-dependent manner, as is well known. However, the combination of cisplatin with ferucarbotran/AMF was significantly more effective than cisplatin alone. This result suggests that it might be possible to reduce the clinically effective dosage of cisplatin by administering it in combination with ferucarbotran/AMF-induced hyperthermia, thereby potentially reducing the incidence of serious cisplatin-related side effects. Further work seems justified to evaluate simultaneous thermo-chemotherapy as a new approach to anticancer therapy.
authors.affiliation: Cardiovascular Research Institute, Yokohama City University, Graduate School of Medicine, 3-9 Fukuura, Yokohama, 236-0004, Japan.
authors.forename: Itaru
authors.initials: I
authors.lastname: Sato
authors.forename: Masanari
authors.initials: M
authors.lastname: Umemura
authors.forename: Kenji
authors.initials: K
authors.lastname: Mitsudo
authors.forename: Mitomu
authors.initials: M
authors.lastname: Kioi
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Nakashima
authors.forename: Toshinori
authors.initials: T
authors.lastname: Iwai
authors.forename: Xianfeng
authors.initials: X
authors.lastname: Feng
authors.forename: Kayoko
authors.initials: K
authors.lastname: Oda
authors.forename: Akiyoshi
authors.initials: A
authors.lastname: Miyajima
authors.forename: Ayako
authors.initials: A
authors.lastname: Makino
authors.forename: Maki
authors.initials: M
authors.lastname: Iwai
authors.forename: Takayuki
authors.initials: T
authors.lastname: Fujita
authors.forename: Utako
authors.initials: U
authors.lastname: Yokoyama
authors.forename: Satoshi
authors.initials: S
authors.lastname: Okumura
authors.forename: Motohiko
authors.initials: M
authors.lastname: Sato
authors.forename: Haruki
authors.initials: H
authors.lastname: Eguchi
authors.forename: Iwai
authors.initials: I
authors.lastname: Tohnai
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Ishikawa
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D002294:Carcinoma, Squamous Cell / Q000473:pathology*; D045744:Cell Line, Tumor; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000494:pharmacology*; D003911:Dextrans; D004305:Dose-Response Relationship, Drug; D005240:Feasibility Studies; D059565:G2 Phase Cell Cycle Checkpoints / Q000187:drug effects; D006258:Head and Neck Neoplasms / Q000473:pathology*; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods*; D060526:Magnetic Fields; D058185:Magnetite Nanoparticles; D009062:Mouth Neoplasms / Q000473:pathology*; D000077195:Squamous Cell Carcinoma of Head and Neck; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D003911:Dextrans; D058185:Magnetite Nanoparticles; C065507:ferumoxides; D002945:Cisplatin